Twist Bioscience Corporation (TWST)
| Market Cap | 5.80B |
| Revenue (ttm) | 126.82M |
| Net Income (ttm) | -135.17M |
| Shares Out | 48.96M |
| EPS (ttm) | -2.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 197,027 |
| Open | 118.81 |
| Previous Close | 117.72 |
| Day's Range | 118.76 - 121.69 |
| 52-Week Range | 74.25 - 214.07 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 120.00 (+0.2%) |
| Est. Earnings Date | Nov 26, 2021 |
About TWST
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; CM...
Financial Performance
In 2020, TWST's revenue was $90.10 million, an increase of 65.67% compared to the previous year's $54.39 million. Losses were -$139.93 million, 30.0% more than in 2019.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for TWST stock is "Buy." The 12-month stock price forecast is 120.00, which is an increase of 0.21% from the latest price.
News
2 Stocks You'll Probably Never Want to Sell
Both are biotech stocks with tremendous long-term opportunities.
Twist Bioscience and the Broad Institute Create Custom Whole Exome Target Enrichment Panel for Clinical Research
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...
Twist Bioscience Appoints Steffen Hellmold as Senior Vice President, Business Development, Data Storage
SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today ...
3 IPO Cathie Wood Stocks to Buy
It's time to follow the money in three Cathie Wood stocks, while sticking to the price charts in order to enjoy smarter money investments. The post 3 IPO Cathie Wood Stocks to Buy appeared first on Inve...
Centogene, Twist Join Forces For Custom Test Kits For Rare Diseases
Centogene NV (NASDAQ: CNTG) and Twist Bioscience Corporation (NASDAQ: TWST) have signed a contract to develop and commercialize custom assay kits for rare diseases. The financial details of the deal wer...
Twist Bioscience and CENTOGENE to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for Mo...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...
Twist Bioscience Expands Expert Custom Alliance Panel Offering
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...
Twist Bioscience Appoints Dennis Cho as Senior Vice President, General Counsel and Chief Ethics and Compliance Officer
SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform...
Twist Bioscience Internally-Discovered Single Domain Antibody TB202-3 Shows Potent Binding to Multiple Strains of SAR...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent bindin...
Twist Bioscience Collaborates with Deep Learning Experts deepCDR on Antibody Library Design
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...
2 Biotech Stocks to Buy Right Now
They both have great growth prospects.
Twist Bioscience Continues Commitment to Deliver Synthetic RNA Controls, now to Fight Delta Plus Variants of COVID-19
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...
Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics
SOUTH SAN FRANCISCO, Calif. & MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience and Adicet Bio collaboration to accelerate the discovery of gamma delta T cell therapies against five undiscl...
Twist Bioscience, Boehringer Ingelheim Joins Forces For Antibody Research Programs
Twist Bioscience Corporation (NASDAQ: TWST) has announced a broad-based research collaboration with Boehringer Ingelheim International GmbH. The collaboration will use Twist's proprietary antibody libra...
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
SOUTH SAN FRANCISCO, Calif. & INGELHEIM, Germany--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA ...
Twist Bioscience to Present at Baird 2021 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...
Twist Bioscience, SomaLogic Team Up For Antibodies, Target Discovery
Twist Bioscience Corporation (NASDAQ: TWST) and SomaLogic announced a partnership to discover novel therapeutic targets and antibodies. Financial and other details of the partnership were not disclosed.
SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies
BOULDER, Colo. & SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (Nasdaq: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, and Twist Biosc...
Twist Bioscience to Present at UBS Genomics 2.0 and Medtech Innovations Summit
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...
Twist Bioscience Stock Falls On Wider Q3 Loss, Sales Beat Estimates; Raises FY21 Guidance
Twist Bioscience Corporation (NASDAQ: TWST) reported a 65% Y/Y increase in its third-quarter revenues to $35 million, beating the Wall Street estimate of $32.27 million, driven by strength in next-gener...
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of -7.89% and 7.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Twist Bioscience Reports Third Quarter Fiscal 2021 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...
Twist Bioscience Appoints Drug Discovery Leader Melissa Starovasnik, Ph.D., to Board of Directors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...
Twist Bioscience (TWST) Expected to Beat Earnings Estimates: Should You Buy?
Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.